Idera Pharmaceuticals NASDAQ:IDRA Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Location: 505 Eagleview Blvd Ste 212, Pennsylvania, 19341-1199, US | Website: www.iderapharma.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing